Detecting cardiovascular problems: Beurer is cooperating with Cardiolyse

Together with the Finnish start-up Cardiolyse, the Ulm-based health specialist Beurer is offering the first comprehensive solution for detecting cardiovascular problems. The partnership is foreseen to enable expansion of the Cardiolyse eHealth platform and heart signal analytics services to the global market as well as further improvement of the product to serve the patient-centric digitalization of the healthcare industry. It is an ECG & HRV predictive analytics platform for real-time remote heart health and fatigue risks monitoring. For this purpose, Beurer ECG devices delivering important viral parameters.

"Cardiovascular disease (CVD) remains the main killer, taking 1 of every 3 lives worldwide. CVD complications are accountable for more than 50% of all deaths among people with diabetes, which unfortunately is a growing population in Europe. And knowing that most cardiac complications could be prevented with early detection, we see our mission in supporting innovative digital healthcare solutions like Cardiolyse", says Beurer Managing Director and Shareholder Marco Bühler. "Artificial intelligence and machine learning applied to healthcare services have a huge potential to pave the way for an automated data-driven clinical decision support for hospital staff, that widely-used Beurer devices are also actively engaged in".

The company's proprietary patent-pending machine-learning algorithms process all vital ECG parameters from Beurer devices and detect CE-certified to 20 types of Arrhythmias, Atrial Fibrillation, Ventricular Hypertrophy, and Myocardial Infarction. The system builds a patient's personal baseline by keeping track of crucial cardiac and lifestyle parameters, placing them on the scale from the individual norm to pathology to deliver reliable cardiac insights. Cardiolyse's alerting feature notifies both patient and his GP on increased stroke or heart attack risks, enabling the prevention of critical heart events in the midterm. As a device-agnostic cloud platform, Cardiolyse cuts off the need for complicated time-consuming integration by pairing its solution with any type of digital ECG device via universal API (application programming interface). The ecosystem is comprised of customized web dashboards for both patients and physicians, as well as independent Android and iOS applications for each user type needs.

"Global healthcare is in obvious and desperate need for disruptive technologies that will support its digital transformation to serve the emerging challenges of both healthcare providers and personal health-conscious patients", commented Anna Starynska, co-founder and CEO at Cardiolyse. "Our primary goal here is to provide timely and data-driven insights for physicians and cardiologists to support the cost-effective patient-centric diagnosticating approach and more accurate self-care solutions for patients. Thanks to Beurer's wide distribution network and Cardiolyse analytics platform, more people will be able to elicit cardiac risks at an early stage and make crucial lifestyle adjustments on time".

Cardiolyse is now on its pre-commercialization stage. The cloud platform is fully operational, with the proprietary algorithms been validated within multiple pieces of research and pilot projects. Specifically, starting from 2016, the company has been involved in the 500,000 ECG recordings analysis initiated by Oxford Nuffield Department of Population Health and China Kadoorie bank.